Skip to main content
PMC home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 2006 Dec;98(12):1953–1957.

Antibody level after hepatitis-B vaccination in hemodialysis patients: impact of dialysis adequacy, chronic inflammation, local endemicity and nutritional status.

Salwa Ibrahim 1, Sharaf el-Din 1, Ibrahim Bazzal 1
PMCID: PMC2569692  PMID: 17225840

Abstract

We prospectively studied the evolution of HBsAg antibody (HBsAb) after primary vaccination (four doses; Engerix B, 40 pg i.m at 0, one, two and six months) in 29 patients who were seronegative (HBsAb <10 IU/L), had not been previously vaccinated and were on hemodialysis. Their mean age was 45.58 +/- 10.98 years, and the hemodialysis duration ranged from 1-21 years. In addition, we assessed dialysis adequacy for all cases on four different occasions beside the estimation of predialysis serum albumin, serum ferritin, C-reactive protein (CRP), transferrin saturation ratio (TSAT), body mass index (BMI) and subjective global assessment (SGA). We measured anti-HBs titer eight weeks after the fourth dose. Our results showed that two patients (6.90%) were nonresponders (HBsAb <10 IU/L) after the completion of vaccination. One patient (3.45%) was a weak responder (10-100 IU/L). Strikingly, 26 patients (89.65%) showed good antibody response (>100 IU/L). HBsAb titers showed no significant correlation with age, duration of HD therapy, serum albumin, CRP, TSAT level, BMI or SGA scores (p > 0.05). Responders to primary vaccination had significantly higher levels of urea reduction ratio (%) and Kt/V compared to nonresponders (63.61 +/- 6.97% and 1.25 +/- 0.15 vs. 52.0 +/- 2.10% and 0.92 +/- 0.13, respectively, P < 0.05). In conclusion, this was a preliminary study showing a very high response to hepatitis-B vaccination among hemodialysis patients that neither correlated with age, systemic inflammation nor nutritional status. Efficient hemodialysis was associated with good response to hepatitis-B vaccine.

Full text

PDF
1953

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Afifi A., Karim M. A. Renal replacement therapy in Egypt: first annual report of the Egyptian Society of Nephrology, 1996. East Mediterr Health J. 1999 Sep;5(5):1023–1029. [PubMed] [Google Scholar]
  2. Buti M., Viladomiu L., Jardi R., Olmos A., Rodriguez J. A., Bartolome J., Esteban R., Guardia J. Long-term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients. Am J Nephrol. 1992;12(3):144–147. doi: 10.1159/000168436. [DOI] [PubMed] [Google Scholar]
  3. Centers for Disease Control and Prevention (CDC) Outbreaks of hepatitis B virus infection among hemodialysis patients-- California, Nebraska, and Texas, 1994. MMWR Morb Mortal Wkly Rep. 1996 Apr 12;45(14):285–289. [PubMed] [Google Scholar]
  4. Chatenoud L., Herbelin A., Beaurain G., Descamps-Latscha B. Immune deficiency of the uremic patient. Adv Nephrol Necker Hosp. 1990;19:259–274. [PubMed] [Google Scholar]
  5. Cheng C. H., Huang C. C., Leu M. L., Chiang C. Y., Wu M. S., Lai P. C. Hepatitis B vaccine in hemodialysis patients with hepatitis C viral infection. Vaccine. 1997 Aug-Sep;15(12-13):1353–1357. doi: 10.1016/s0264-410x(97)00037-6. [DOI] [PubMed] [Google Scholar]
  6. Cheng C. H., Huang C. C., Leu M. L., Chiang C. Y., Wu M. S., Lai P. C. Hepatitis B vaccine in hemodialysis patients with hepatitis C viral infection. Vaccine. 1997 Aug-Sep;15(12-13):1353–1357. doi: 10.1016/s0264-410x(97)00037-6. [DOI] [PubMed] [Google Scholar]
  7. DaRoza Gerald, Loewen Andrea, Djurdjev Ognjenka, Love Janet, Kempston Cathy, Burnett Shelley, Kiaii Mercedeh, Taylor Paul A., Levin Adeera. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis. 2003 Dec;42(6):1184–1192. doi: 10.1053/j.ajkd.2003.08.019. [DOI] [PubMed] [Google Scholar]
  8. Dacko C., Holley J. L. The influence of nutritional status, dialysis adequacy, and residual renal function on the response to hepatitis B vaccination in peritoneal dialysis patients. Adv Perit Dial. 1996;12:315–317. [PubMed] [Google Scholar]
  9. Daugirdas J. T. Simplified equations for monitoring Kt/V, PCRn, eKt/V, and ePCRn. Adv Ren Replace Ther. 1995 Oct;2(4):295–304. doi: 10.1016/s1073-4449(12)80028-8. [DOI] [PubMed] [Google Scholar]
  10. Docci D., Cipolloni P. A., Baldrati L., Capponcini C., Turci F., Feletti C. Immune response to a recombinant hepatitis B vaccine in hemodialysis patients. Int J Artif Organs. 1990 Jul;13(7):451–453. [PubMed] [Google Scholar]
  11. Eardley Kevin S., Jones Helen E., Osman Husam, Smith Steve A. Efficacy of the accelerated hepatitis B vaccination schedule used in haemodialysis patients post-exposure to virus: a single-centre experience. Nephrol Dial Transplant. 2002 Nov;17(11):1982–1987. doi: 10.1093/ndt/17.11.1982. [DOI] [PubMed] [Google Scholar]
  12. Elwell Rowland J., Neumann Marianne, Bailie George R. Factors associated with long-term antibody production induced by hepatitis B vaccine in patients undergoing hemodialysis: a retrospective cohort study. Pharmacotherapy. 2003 Dec;23(12):1558–1563. doi: 10.1592/phco.23.15.1558.31954. [DOI] [PubMed] [Google Scholar]
  13. Fabrizi F., Martin P., Dixit V., Bunnapradist S., Dulai G. Meta-analysis: the effect of age on immunological response to hepatitis B vaccine in end-stage renal disease. Aliment Pharmacol Ther. 2004 Nov 15;20(10):1053–1062. doi: 10.1111/j.1365-2036.2004.02264.x. [DOI] [PubMed] [Google Scholar]
  14. Fernández E., Betriu M. A., Gómez R., Montoliu J. Response to the hepatitis B virus vaccine in haemodialysis patients: influence of malnutrition and its importance as a risk factor for morbidity and mortality. Nephrol Dial Transplant. 1996 Aug;11(8):1559–1563. [PubMed] [Google Scholar]
  15. Girndt M., Köhler H., Schiedhelm-Weick E., Schlaak J. F., Meyer zum Büschenfelde K. H., Fleischer B. Production of interleukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int. 1995 Feb;47(2):559–565. doi: 10.1038/ki.1995.70. [DOI] [PubMed] [Google Scholar]
  16. Girndt M., Sester M., Sester U., Kaul H., Köhler H. Defective expression of B7-2 (CD86) on monocytes of dialysis patients correlates to the uremia-associated immune defect. Kidney Int. 2001 Apr;59(4):1382–1389. doi: 10.1046/j.1523-1755.2001.0590041382.x. [DOI] [PubMed] [Google Scholar]
  17. Girndt M., Sester U., Sester M., Deman E., Ulrich C., Kaul H., Köhler H. The interleukin-10 promoter genotype determines clinical immune function in hemodialysis patients. Kidney Int. 2001 Dec;60(6):2385–2391. doi: 10.1046/j.1523-1755.2001.00062.x. [DOI] [PubMed] [Google Scholar]
  18. Kara Ismail Hamdi, Yilmaz Mehmet Emin, Suner Ali, Kadiroglu Ali Kemal, Isikoglu Bunyamin. The evaluation of immune responses that occur after HBV infection and HBV vaccination in hemodialysis patients. Vaccine. 2004 Sep 28;22(29-30):3963–3967. doi: 10.1016/j.vaccine.2004.04.001. [DOI] [PubMed] [Google Scholar]
  19. Kovacić Vedran, Sain Milenka, Vukman Valentina. Poboljsava li ucinkovitija hemodijaliza odgovor na cijepljenje protiv virusa hepatitisa B? Lijec Vjesn. 2004 May-Jun;126(5-6):133–137. [PubMed] [Google Scholar]
  20. Magnani G., Calzetti C., Campari M., Lehndorff H., Pizzaferri P., Rossi E. Risposta immune al vaccino anti epatite B e durata della protezione in un centro dialisi. Acta Biomed Ateneo Parmense. 1987;58(1-2):41–47. [PubMed] [Google Scholar]
  21. Majdan M., Polz M., Ksiazek A., Janicka L., Kozioł M., Swatowski A., Orłowska G. Odpowiedź na szczepienie szczepionka przeciw wirusowemu zapaleniu watroby typu B chorych hemodializowanych i dializowanych otrzewnowo-doświadczenia własne. Przegl Lek. 1995;52(6):307–310. [PubMed] [Google Scholar]
  22. Muszytowski M., Manitius J., Ruszkiewicz-Fołda M. Wystepowanie odpowiedzi na szczepienie przeciwko HBV u chorych przewlekle hemodializowanych i zakazonych wirusem C (HCV). Przegl Lek. 1996;53(5):417–419. [PubMed] [Google Scholar]
  23. Navarro J. F., Teruel J. L., Mateos M. L., Marcen R., Ortuno J. Antibody level after hepatitis B vaccination in hemodialysis patients: influence of hepatitis C virus infection. Am J Nephrol. 1996;16(2):95–97. doi: 10.1159/000168977. [DOI] [PubMed] [Google Scholar]
  24. Pasko M. T., Bartholomew W. R., Beam T. R., Jr, Amsterdam D., Cunningham E. E. Long-term evaluation of the hepatitis B vaccine (Heptavax-B) in hemodialysis patients. Am J Kidney Dis. 1988 Apr;11(4):326–331. doi: 10.1016/s0272-6386(88)80138-0. [DOI] [PubMed] [Google Scholar]
  25. Peces R., de la Torre M., Alcázar R., Urra J. M. Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients. Am J Kidney Dis. 1997 Feb;29(2):239–245. doi: 10.1016/s0272-6386(97)90036-6. [DOI] [PubMed] [Google Scholar]
  26. Qirbi N., Hall A. J. Epidemiology of hepatitis B virus infection in the Middle East. East Mediterr Health J. 2001 Nov;7(6):1034–1045. [PubMed] [Google Scholar]
  27. Roozbeh Jamshid, Moini Maryam, Lankarani Kamran Bagheri, Sagheb Mohamad Medhi, Shahpoori Sedigheh, Bastani Bahar. Low dose intradermal versus high dose intramuscular hepatitis B vaccination in patients on chronic hemodialysis. ASAIO J. 2005 May-Jun;51(3):242–245. doi: 10.1097/01.mat.0000161935.66158.97. [DOI] [PubMed] [Google Scholar]
  28. Tele S. A., Martins R. M., Lopes C. L., dos Santos Carneiro M. A., Souza K. P., Yoshida C. F. Immunogenicity of a recombinant hepatitis B vaccine (Euvax-B) in haemodialysis patients and staff. Eur J Epidemiol. 2001;17(2):145–149. doi: 10.1023/a:1017918218784. [DOI] [PubMed] [Google Scholar]
  29. Weinstein Talia, Chagnac Avry, Boaz Mona, Ori Yaacov, Herman Michal, Zevin Dina, Schmilovitz-Weiss Hemda, Gafter Uzi. Improved immunogenicity of a novel third-generation recombinant hepatitis B vaccine in patients with end-stage renal disease. Nephron Clin Pract. 2004;97(2):c67–c72. doi: 10.1159/000078403. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES